Enliven Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -79 | -79 | ||
EBITDA | -26,816 | -26,988 | -24,525 | -25,908 |
EBIT | -26,896 | -27,068 | -24,603 | -25,987 |
Net Income | -23,180 | -23,156 | -19,950 | -22,738 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -17,203 | -12,215 | -20,437 | -23,381 |
Cash | 124,117 | 100,621 | 96,871 | 149,219 |
Basic Shares | 49,858 | 48,267 | 48,075 | 42,045 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -297 | -622 | -99 | |
EBITDA | -104,554 | -81,932 | -38,576 | -24,647 |
EBIT | -82,229 | -38,791 | -24,762 | |
Net Income | -89,024 | -71,584 | -37,750 | -24,718 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -73,236 | -61,418 | -32,689 | -19,325 |
Cash | 124,117 | 100,141 | 75,536 | 110,024 |
Basic Shares | 47,072 | 35,546 | 6,248 | 7,814 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.46 |
2024-09-30 | -$0.47 |
2024-06-30 | -$0.41 |
2024-03-31 | -$0.54 |
